Name | Title | Contact Details |
---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Walgreen Co is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CARGO Therapeutics is a biotechnology company that is developing and delivering CAR T cell therapies to cure more cancer patients. Their cell therapies focus on addressing the primary mechanisms of failure, or resistance and relapse, to the currently a...
Redox Pharmaceutical Corp. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients.